Regeneron Pharmaceuticals Inc., Tarrytown, New York, was awarded a $2,940,000,000 modification (P00005) to contract W15QKN-21-C-0014 for 1,400,000 REGEN-COV antibody therapeutic doses. Work will be performed in Tarrytown, New York, with an estimated completion date of July 31, 2022. Fiscal 2021 research, development, test and evaluation, Army funds in the amount of $2,940,000,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity.